Background {#Sec1}
==========

The modern concept of reducing both the spectrum of antimicrobial therapy and its potential to promote resistance \[[@CR1]\], usually called *de-escalation*, is strongly recommended in all of the recently published guidelines for antibiotic stewardship \[[@CR2], [@CR3]\]. Several definitions have been used to describe this process \[[@CR1], [@CR4]--[@CR7]\]. Despite the limited evidence, de-escalation has been recommended to decrease the likelihood of emergence of resistant organisms \[[@CR8]\], to optimize activity, and to reduce toxicity and costs \[[@CR3]\].

Two types of critically ill patients have been investigated: cohorts with a specific disease---mainly ventilator-associated pneumonia (VAP) \[[@CR5], [@CR9]--[@CR13]\]---and large mixed populations with severe sepsis or septic shock or patients who require emergency empiric antibiotic therapy \[[@CR4], [@CR14]--[@CR19]\]. In a recent systematic review, Tabah et al. identified isolation of multiresistant pathogens, polymicrobial infections, and intra-abdominal infections as factors negatively associated with de-escalation \[[@CR20]\]. Only a few studies have addressed this issue in the context of intra-abdominal infections \[[@CR4], [@CR14], [@CR18], [@CR21], [@CR22]\]. The high frequency of polymicrobial infection \[[@CR23], [@CR24]\] and multidrug-resistant (MDR) organisms \[[@CR23], [@CR24]\] as well as the presence of fungi \[[@CR17], [@CR25]\] in this setting might raise specific concerns, especially in health care-associated intra-abdominal infections (HCIAI).

The purpose of the present study was to analyze the frequency of de-escalation, the factors that could interfere with this process, and their clinical consequences in a cohort of intensive care unit (ICU) patients with HCIAI.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

From January 1999 through December 2011, all consecutive patients admitted to our ICU for the management of HCIAI were prospectively included in a database and their medical charts were retrospectively reviewed. The study was approved by the local institutional review board (CEERB CHU Bichat Paris VII University, APHP, Paris, France), which waived the need for signed informed consent.

Selection of cases and inclusion criteria {#Sec4}
-----------------------------------------

Postoperative peritonitis was defined as the first macroscopic findings of intra-abdominal infection combined with positive fluid culture yielding at least one microorganism (bacteria or fungi) at the time of reoperation (day 0) following a first abdominal surgery \[[@CR24]\]. Several patients had to be excluded from the analysis due to early change in their clinical status before de-escalation could be instituted: patients who died during the first 3 days following surgery (microbiologic results not yet obtained), those who were discharged during the first 3 days (incapacity to adequately follow clinical outcome and antibiotic therapy), and those who underwent early reoperation during the first 3 days (high proportion of persistent infection and prolonged antibiotic therapy). Similarly, we excluded patients with negative microbiologic samples, since the concept of de-escalation is questionable and the interpretation of the results is difficult. In these patients, empiric anti-infective therapy was discontinued. Drainage of abscesses, debridement of infected and necrotic tissues, abdominal cavity cleansing, irrigation, and definitive control of the source of contamination were performed according to the surgical principles used for the management of abdominal sepsis \[[@CR26]\]. Ostomy was preferred to primary anastomosis. No open-wound management was performed, and the abdomen was not irrigated after surgery.

Microbiologic data {#Sec5}
------------------

Peritoneal fluid samples were systematically collected during surgery and were immediately sent to the bacteriology laboratory \[[@CR24]\]. Cultures were performed with identification and susceptibility testing for Gram-positive and Gram-negative aerobe bacteria, anaerobes, and fungi. Antibiotic susceptibility was determined for each organism by the disk diffusion method, according to the criteria of the Antibiogram Committee of the French Society for Microbiology \[[@CR27]\]. MDR bacteria were defined as those resistant to three or more antimicrobial classes \[[@CR28]\]: methicillin-resistant *Staphylococcus aureus* and methicillin-resistant coagulase-negative staphylococci; ampicillin-resistant enterococci; Enterobacteriaceae producing an extended-spectrum β-lactamase or producing a derepressed cephalosporinase; and/or nonfermenting Gram-negative bacilli (NFGNB) resistant to piperacillin-tazobactam, ceftazidime, or imipenem-cilastatin, or producing an extended-spectrum β-lactamase.

Management of antibiotic therapy {#Sec6}
--------------------------------

Empiric anti-infective therapy, systematically started at day 0, took into account the severity of the case and usually combined piperacillin-tazobactam or imipenem-cilastatin with amikacin and vancomycin \[[@CR23]\], possibly associated with antifungal therapy (mainly fluconazole) based on presumed risk factors \[[@CR25], [@CR29]\]. Definitive anti-infective therapy was adapted on the basis of the results of identification and antibiotic susceptibility testing (≥48 h). In both situations, therapy was considered appropriate when all cultured organisms (bacteria and fungi) were targeted. Anti-infective therapy was prescribed by the senior ICU physicians following discussion with the consultant microbiologist on a daily basis.

The following changes were considered to constitute de-escalation \[[@CR1]\]: withdrawal of one agent (β-lactam, aminoglycoside, fluoroquinolone, vancomycin, antifungal agent) or narrowing spectrum of activity (β-lactam agents) and/or switch from combination to monotherapy. Discontinuation of unduly administered agents was also recorded. Changes among cefepime, ceftazidime, piperacillin-tazobactam, and ticarcillin-clavulanate were not considered to be significant changes of the spectrum of coverage \[[@CR1]\].

In patients without de-escalation, two situations were identified according to previous definitions \[[@CR4]\]. Maintained empiric treatment without modification was called unchanged therapy \[[@CR4]\]. Escalation was defined as addition or switch to a new broad-spectrum anti-infective agent (carbapenems, glycopeptides, fluoroquinolones) \[[@CR4]\] or upgrade to broader-spectrum β-lactams \[[@CR1]\]. When changes combined escalation and de-escalation, the patient was assigned to the escalation group \[[@CR4]\]. In summary, a patient receiving empiric therapy with piperacillin-tazobactam plus amikacin who was subsequently switched to piperacillin and vancomycin was classified as having withdrawal of one agent and escalation.

Data collection {#Sec7}
---------------

All patients' charts were reviewed. Demographic data and severity scores (Simplified Acute Physiology Score II score \[[@CR30]\] and Sequential Organ Failure Assessment \[SOFA\] score \[[@CR31]\]) were recorded on admission to the ICU. The severity of the underlying medical condition and the presence of chronic diseases \[[@CR32]\] were recorded. The characteristics of initial surgery were recorded.

The following clinical and severity characteristics were assessed at day 0, day 3, and day 7 after surgery for patients still in the ICU \[[@CR24], [@CR33], [@CR34]\]: temperature, white blood cell count (WBC), serum creatinine, and SOFA score. Patients meeting the following three criteria at day 3 were arbitrarily defined as improving: (1) a SOFA score that decreased more than 2 points at day 3 versus day 0 or a SOFA score of 0 points, (2) a WBC that decreased more than 5000/mm^3^ between day 0 and day 3 or WBC less than 12,500/mm^3^, and (3) a temperature decrease greater than 0.5 °C between day 0 and day 3 or temperature greater than or equal to 36.5 °C and less than 38.1 °C. Similar analyses were used at day 7 to compare changes in these criteria between days 3 and 7. Medical and surgical complications, additional reoperations for persistence of the initial infection or superinfections (including MDR organisms), death between days 3 and 28 following surgery, and discharge from the hospital were assessed.

Statistical analysis {#Sec8}
--------------------

Results are expressed as median and interquartile range (IQR) or number and proportion. Statistical significance was defined as *p* \< 0.05. For statistical analysis, we used R version 2.14.1 software (R Foundation for Statistical Computing, Vienna, Austria). For comparisons between antibiotic strategy groups (de-escalation, no change, or escalation), we used the χ^2^ test and Fisher's exact test for discrete variables and unpaired Wilcoxon tests for quantitative variables. The effect of antibiotic strategy on day 28 mortality was assessed with a Kaplan-Meier survival curve and tested with a log-rank test.

Three multivariable models were developed (1) to identify risk factors for de-escalation and (2) to assess the association between antibiotic strategy (de-escalation, no change, or escalation) and day 28 or in-hospital mortality. In univariate analysis for these three models, we used Fisher's exact tests and Wilcoxon tests. Unadjusted ORs or HRs were calculated. Variables with a *p* value less than 0.2 in univariate analysis were entered into a multivariate logistic regression model or a Cox proportional hazards model with backward selection. For day 28 and in-hospital mortality, the antibiotic strategy was forced until the end of the selection process. Logistic models were evaluated for discrimination with the c-statistic and for calibration with the Hosmer-Lemeshow test.

Results {#Sec9}
=======

Epidemiologic and clinical characteristics {#Sec10}
------------------------------------------

During the study period, 311 ICU patients were admitted for the management of HCIAI. Figure [1](#Fig1){ref-type="fig"} displays a flowchart of patients through the study. Overall, 105 patients were excluded, resulting in 206 patients for whom the de-escalation process was analyzed. De-escalation was performed in 110 patients (53 % of the analyzed population), and no de-escalation was observed in 96 patients (47 %) (escalation in 65 patients \[32 %\] and unchanged regimen in 31 patients \[15 %\]). De-escalation was never performed after discharge from the ICU. The frequency of de-escalation remained stable over the study period, ranging between 47 % and 63 % of the analyzed population (not significant; data not shown). Clinical characteristics were similar at day 0 in both groups (Table [1](#Tab1){ref-type="table"}). In the non-de-escalation group, a significantly increased severity was observed in the patients with an unchanged regimen versus escalation (Table [1](#Tab1){ref-type="table"}).Fig. 1Flowchart of the 206 patients studied. *ICU* intensive care unitTable 1Demographic and clinical characteristics of the 206 patients with or without subsequent antibiotic de-escalationCharacteristicDe-escalation (*n* = 110)No de-escalation (*n* = 96)Escalation (*n* = 65)No change (*n* = 31)Male sex, *n* (%)61 (55)56 (58)35 (54)21 (68)Age, years, median (IQR)61 (47--72)66 (51--75)^a^63 (47--75)70 (58--77)Comorbidities Fatal underlying disease30 (27)32 (33)21 (32)11 (35) Cancer, *n* (%)37 (34)36 (38)23 (35)13 (42) Diabetes, *n* (%)17 (15)15 (16)9 (14)6 (19)Time since initial surgery, days, median (IQR)7 (5--12)7 (4--10)6 (3--9)8 (5--10)Antibiotic therapy before reoperation, *n* (%)73 (66)68 (71)47 (72)21 (68)Broad-spectrum interim antibiotic, *n* (%)34 (31)37 (39)27 (42)10 (32)Intraoperative diagnosis Anastomotic leakage, *n* (%)45 (41)27 (28)19 (29)8 (26) Perforation or ischemia, *n* (%)33 (30)36 (38)20 (31)16 (52)^a\#^ Purulent collection, *n* (%)19 (17)17 (18)13 (20)4 (13) No cause, *n* (%)19 (17)20 (21)15 (23)5 (16)Contamination below transverse mesocolon, *n* (%)82 (75)74 (77)50 (77)24 (77)Characteristics at the time of ICU admission Bacteremia, *n* (%)26 (24)17 (18)14 (22)3 (10) SAPS II score, median (IQR)45 (34--54)47 (35--57)44 (34--56)51 (42--61)^a\#^ SOFA score, median (IQR)7 (4--9)8 (4--10)7 (4--9)9 (6--10) Hemodynamic failure^b^, *n* (%)65 (59)65 (68)41 (63)24 (77) Respiratory failure^b^, *n* (%)54 (49)40 (42)26 (40)14 (45) Renal failure^b^, *n* (%)21 (19)18 (19)13 (20)5 (16)*IQR* interquartile range, *SAPS II* Simplified Acute Physiology Score II, *SOFA* Sequential Organ Failure AssessmentPatients without de-escalation were also analyzed in terms of subsequent antibiotic escalation or no change. Results are expressed as number and proportions or median (IQR)^a^ *p* \< 0.05 versus de-escalation^b^SOFA score of 3 or 4 for each organ^\#^ *p* \< 0.05 versus escalation

Microbiologic analysis {#Sec11}
----------------------

Overall, 618 microorganisms from peritoneal samples were cultured (311 in patients without de-escalation, including 101 organisms in the unchanged group and 210 in the escalation group). Similar microbiologic results were observed between de-escalation and no de-escalation groups (data not shown), except for lower proportions of *Enterococcus faecium* (9 \[3 %\] versus 18 \[7 %\] without de-escalation, respectively; *p* \< 0.01) and non-fermenting Gram-negative bacilli (9 \[3 %\] versus 22 \[8 %\], respectively; *p* \< 0.01). Among patients without de-escalation, increased proportions of Gram-negative bacteria and *Enterobacteriaceae* were observed in patients with unchanged regimen compared with those whose regimen was escalated (47 \[49 %\] versus 69 \[37 %\], respectively \[*p* \< 0.05\]; and 38 \[40 %\] versus 52 \[28 %\] \[*p* \< 0.05\]). In the de-escalation group, 23 (21 %) of 110 patients harbored MDR strains compared with 54 (56 %) of 96 patients in the non-de-escalation group (*p* \< 0.01) (Table [2](#Tab2){ref-type="table"}).Table 2Multidrug-resistant bacteria cultured from peritoneal fluid of patients with or without subsequent antibiotic de-escalationMicroorganismsDe-escalationNo de-escalationEscalationNo changeTotal number of multidrug-resistant bacteria, *n* (%)29 (9)74 (24)^a^58 (28)16 (16)^b^Gram-positive bacteria, *n* (%)15 (5)39 (13)^a^33 (16)6 (6)^b^ Enterococci, *n* (%)3 (1)9 (3)7 (3)2 (2) Staphylococci, *n* (%)12 (4)29 (9)25 (12)4 (4)   *Staphylococcus aureus*, *n* (%)--8 (3)6 (3)2 (2)Gram-negative bacteria, *n* (%)14 (5)35 (11)^a^25 (12)10 (10)  *Enterobacteriaceae*, *n* (%)10 (3)24 (8)18 (9)6 (6)   *Escherichia coli*, *n* (%)1 (0)11 (4)8 (4)3 (3)   *Enterobacter* spp., *n* (%)5 (2)9 (3)8 (4)1 (1) Nonfermenting Gram-negative bacilli, *n* (%)3 (1)11 (4)7 (3)4 (4)   *Pseudomonas* spp., *n* (%)2 (1)6 (2)4 (2)2 (2)Total number of cultured bacteria, *n*307311210101Among the 96 patients without de-escalation, the results were analyzed in terms of subsequent antibiotic escalation or no change^a^ *p* \< 0.01 versus de-escalation^b^ *p* \< 0.05 versus escalation

Anti-infective therapy {#Sec12}
----------------------

De-escalation was performed on a microbiologic basis in a median delay of 3 days (IQR 2--4) after surgery. Empiric treatments and the procedures applied for de-escalation at day 3 are described in Table [3](#Tab3){ref-type="table"}. Empiric use of combination therapy, carbapenems, glycopeptides, and antifungal agents were significantly more frequent in the de-escalation group. Among antifungal agents, echinocandins were minimally prescribed for empiric therapy (six patients in the de-escalation group with discontinuation in all but one case and one switch to azoles, one patient in the non-de-escalation group).Table 3Anti-infective regimens in patients with or without de-escalation and clinical characteristics at day 3De-escalation (*n* = 110)No de-escalation (*n* = 96)Escalation (*n* = 65)No change (*n* = 31)Empiric antibiotic therapy Monotherapy, *n* (%)13 (12)32 (33)^a^20 (31)12 (29) Combination of two drugs, *n* (%)40 (36)34 (35)26 (40)8 (26) Combination of three drugs or more, *n* (%)57 (49)30 (33)^b^19 (29)11 (35) Carbapenem, *n* (%)35 (32)15 (16)^a^10 (15)5 (16) Piperacillin-tazobactam, *n* (%)67 (61)60 (63)40 (62)20 (65) Vancomycin, *n* (%)57 (52)23 (24)^a^15 (23)8 (26) Aminoglycosides, *n* (%)59 (54)33 (34)^a^27 (42)6 (19)^b^ Fluoroquinolones, *n* (%)6 (5)11 (11)10 (15)1 (3)Antifungal therapy, *n* (%)47 (43)23 (24)^a^11 (17)12 (39)^b^ Azoles, *n* (%)41 (37)20 (21)^a^9 (14)11 (35)^b^Adequate empiric therapy, *n* (%)100 (91)37 (39)^a^9 (14)28 (90)^c^Reevaluation of antibiotic therapy Discontinuation of carbapenems^d^, *n* (%)27/35 (77)4/15 (27)4/10 (40)-- Discontinuation of piperacillin-tazobactam^d^, *n* (%)50/67 (75)25/60 (42)25/40 (63)-- Discontinuation of vancomycin^d^, *n* (%)46/57 (81)6/23 (26)6/15 (40)-- Discontinuation of aminoglycosides^d^, *n* (%)54/59 (92)21/33 (64)21/27 (78)-- Discontinuation of fluoroquinolones^d^, *n* (%)2/6 (33)6/11 (55)6/10 (60)-- Discontinuation of antifungal agent ^d^, *n* (%)23/47 (49)4/23 (17)4/11 (36)-- Withdrawal of at least one agent, *n* (%)110 (100)42 (47)^a^42 (65)-- Narrowing spectrum, *n* (%)74 (67)18 (19)^a^18 (28)-- Switch to monotherapy, *n* (%)54 (49)7 (7)^a^7 (11)-- Interruption of unnecessary agent, *n* (%)78 (71)20 (21)^a^20 (31)--Clinical changes between days 0 and 3 Changes in SOFA score, median (IQR)−2 (−4 to -1)−2 (−4 to 0)−2 (−4 to 0)−2 (−3 to 0) Decreased SOFA score, *n* (%)69 (63)57 (59)38 (58)19 (61) Decreased temperature, *n* (%)69 (63)64 (67)41 (63)23 (74) Decreased WBC, *n* (%)38 (35)32 (33)23 (35)9 (29) Clinical improvement at day 3, *n* (%)17 (15)18 (19)14 (22)4 (13)*IQR* interquartile range, *SOFA* Sequential Organ Failure Assessment, *WBC* white blood cell countAmong those without de-escalation, the results were analyzed in terms of subsequent antibiotic escalation or no change. Results are expressed as number and proportion of the total number of patients^a^ *p* \< 0.01 versus de-escalation^b^ *p* \< 0.05 versus de-escalation^c^ *p* \< 0.01 versus escalation therapy^d^Proportions are expressed as the number of discontinuations of the drug to the total number of patients empirically receiving this class of drug

When taking into account the criteria for de-escalation, we found that 33 patients met three criteria (withdrawing, narrowing, and switching) in the de-escalation group but none of those who did not de-escalate. However, two criteria (withdrawing and narrowing) were reported in 17 patients in the non-de-escalation group. No clinical change between days 0 and 3 allowed patients who were subsequently de-escalated to be differentiated from those who did not (Table [3](#Tab3){ref-type="table"}).

Determinants of de-escalation in multivariate analysis were adequate empiric therapy (OR 9.60, 95 % CI 4.02--22.97, *p* \< 0.001), empiric use of vancomycin (OR 3.39, 95 % CI 1.46--7.87, *p* = 0.004), carbapenems (OR 2.64, 95 % CI 1.01--6.91, *p* = 0.04), and aminoglycosides (OR 2.31, 95 % CI 1.08--4.94, *p* = 0.03), while presence of NFGNB (OR 0.28, 95 % CI 0.09--0.89, *p* = 0.03) and presence of MDR bacteria (OR 0.21, 95 % CI 0.09--0.52, *p* \< 0.001) were the risk factors for non-de-escalation (c-index 0.880, 95 % CI 0.832--0.928, Hosmer-Lemeshow test *p* = 0.14) (Table [4](#Tab4){ref-type="table"}).Table 4Uni- and multivariate analyses of risk factors for de-escalationUnivariate analysisMultivariate analysisDe-escalation (*n* = 110)No de-escalation (*n* = 96)Unadjusted odds ratio (95 % CI)*p* value^a^Adjusted odds ratio (95 % CI)*p* valueAt time of admission Age, years61 (47--72)66 (51--75)0.98 (0.97--0.99)0.049---- Emergency surgery37 (34)44 (46)0.60 (0.34--1.05)0.087 Anastomotic leakage45 (41)27 (28)1.76 (0.98--3.17)0.058---- Empiric antibiotic monotherapy13 (12)32 (33)0.26 (0.13--0.54)\<0.01----  Initial use of carbapenems35 (32)15 (16)2.52 (1.27--4.98)0.0092.64 (1.01--6.91)0.047  Initial use of vancomycin57 (52)23 (24)3.41 (1.87--6.21)\<0.00013.39 (1.46--7.87)0.004  Initial use of aminoglycosides59 (54)33 (34)2.20 (1.25--3.88)0.0072.31 (1.08--4.94)0.031  Initial use of fluoroquinolones6 (5)11 (11)0.44 (0.15--1.22)0.134  Initial use of antifungal agents47 (43)23 (24)2.36 (1.29--4.32)0.005----At day 3 Presence of *Enterococcus faecium*8 (7)18 (19)0.33 (0.14--0.82)0.019---- Presence of streptococci31 (28)17 (18)1.82 (0.93--3.55)0.098---- Presence of staphylococci25 (23)35 (36)0.51 (0.27--0.94)0.032---- Presence of NFGNB8 (7)22 (23)0.26 (0.11--0.62)0.0020.28 (0.09--0.89)0.031 Presence of MDR strains23 (21)54 (56)0.20 (0.11-- 0.37)\<0.00010.21 (0.09--0.52)0.0007 Presence of fungi30 (27)41 (43)0.50 (0.28--0.90)0.027---- Adequate empiric therapy100 (91)37 (39)15.95 (7.38--34.40)\<0.00019.60 (4.02--22.97)\<0.0001*MDR* multidrug-resistant, *NFGNB* nonfermenting Gram-negative bacilliThe c-index of the final model is 0.880 (95 % CI 0.832--0.928), and the Hosmer-Lemeshow test *p* value is 0.14^a^ *p* values are derived from Fisher's exact test or Wilcoxon test

At day 3, no difference was observed between patients with an unchanged regimen and those who underwent escalation, except for the higher proportions of aminoglycosides and antifungal therapy and the very low proportion adequate empiric therapy (Table [3](#Tab3){ref-type="table"}).

Clinical evaluation following de-escalation {#Sec13}
-------------------------------------------

When comparing the patients who were de-escalated and those who did not de-escalate, we found no significant difference between days 3 and 7 (Table [5](#Tab5){ref-type="table"}). In addition, no significant difference in morbidity or mortality criteria was observed between these two groups.Table 5Clinical presentation at day 7 of empiric therapy and outcome in patients with or without de-escalationDe-escalation (*n* = 110)No de-escalation (*n* = 96)Escalation (*n* = 65)No change (*n* = 31)Definitive anti-infective therapy Monotherapy, *n* (%)64 (58)21 (22)9 (14)12(29)^a^ Combination of two drugs, *n* (%)33 (30)39 (41)31 (48)8 (26)^b^ Combination of three drugs or more, *n* (%)13 (12)36 (38)25 (38)11 (35) Use of carbapenems, *n* (%)5 (5)23 (24)^a^18 (28)5 (16) Use of piperacillin-tazobactam, *n* (%)28 (25)39 (41)^b^19 (29)20 (65)^a^ Use of vancomycin, *n* (%)11 (10)41 (43)^a^33 (51)8 (26)^b^ Use of antifungals, *n* (%)29 (26)43 (45)^a^31 (48)12 (39) Use of azoles, *n* (%)28 (25)39 (41)^b^28 (43)11 (35) Use of echinocandins, *n* (%)1 (1)3 (3)3 (5)-- Duration of anti-infective therapy, days, median (IQR)10 (10--14)10 (10--14)10 (10--14)10 (10--14)Clinical changes between days 3 and 7 Number of cases at day 791755124  Changes in SOFA score^c^, median (IQR)−1 (−3 to 0)−2 (−4 to 0)−2 (−4 to 0)−2 (−4 to 0)  Decreased SOFA score^c^, *n* (%)57 (63)48 (64)35 (54)13 (42)  Decreased temperature^c^, *n* (%)38 (42)36 (48)27 (42)9 (29)  Decreased WBC^c^, *n* (%)31 (34)17 (23)12 (18)5 (16)  Clinical improvement at day 7^c^, *n* (%)16 (18)9 (12)9 (14)-- Discharge between days 3 and 7, *n* (%)20 (22)15 (20)10 (20)5 (21) Death between days 3 and 7, *n* (%)1 (1)3 (4)2 (4)1 (4)Medical complications12 (12)14 (16)6 (10)8 (29)Surgical complications26 (25)21 (24)10 (17)11 (39)^b^Reoperation, *n* (%)38 (35)35 (36)19 (29)16 (51)^b^Time to reoperation, days, median (IQR)6 (5--9)6 (5--8)5 (4--8)7 (6--10)Superinfection on subsequent reoperation^d^, *n* (%)23 (61)23 (66)13 (68)10 (63)Emergence of MDR strains^d^, *n* (%)21 (55)20 (57)11 (58)9 (56)Emergence of ESBL *Enterobacteriaceae* ^d^, *n* (%)5 (13)5 (14)3 (16)2 (13)Emergence of MDR NFGNB^d^, *n* (%)9 (24)5 (14)2 (11)3 (19)Emergence of MRSA^d^, *n* (%)9 (24)8 (23)6 (32)2 (13)Duration of mechanical ventilation^e^, days, median (IQR)7 (3--13)7 (3--11)7 (2--10)7 (3--15)ICU length of stay^e^, days, median (IQR)12 (8--20)12 (8--21)12 (8--21)14 (5--23)Survival at day 28, *n* (%)91 (83)72 (75)51 (78)21 (68)ICU mortality rate, *n* (%)23 (21)32 (33)^b^18 (28)14 (45)Hospital mortality rate, *n* (%)25 (23)33 (34)19 (29)14 (45)*ESBL* extended-spectrum β-lactamase, *ICU* intensive care unit, *IQR* interquartile range, *MDR* multidrug-resistant, MRSA methicillin-resistant *Staphylococcus aureus*, *NFGNB* nonfermenting Gram-negative bacilli, *SOFA* Sequential Organ Failure Assessment, *WBC* white blood cell countAmong those without de-escalation, the results were analyzed in terms of subsequent antibiotic escalation or no change^a^ *p* \< 0.01 versus escalation therapy^b^ *p* \< 0.05 versus escalation therapy^c^Results expressed as number of patients at day 7 in the same group^d^Results expressed as number of patients who underwent reoperation in the same group^e^Results calculated for ICU survivor patients

No significant differences in morbidity or mortality criteria were observed between patients who underwent escalation and those with an unchanged regimen, except for significantly increased proportions of surgical complications and reoperations in patients with an unchanged regimen. The risk factors for death at day 28 following surgery in a Cox model are presented in Table [6](#Tab6){ref-type="table"}. The survival rate expressed by a Kaplan-Meier curve was similar between groups (log-rank test *p* value 0.176) (Fig. [2](#Fig2){ref-type="fig"}).Table 6Uni- and multivariate analyses of risk factors for 28-day mortalityUnivariate analysisMultivariate analysisDeath at day 28 (*n* = 43)Survival at day 28 (*n* = 163)Unadjusted hazard ratio (95 % CI)*p* value^a^Adjusted hazard ratio (95 % CI)*p* valueAge, years69 (56--78)62 (46--72)1.022 (1.003--1.042)0.0231.034 (1.011--1.059)0.004Emergency surgery24 (56)57 (35)2.072 (1.135--3.783)0.015----Surgery below the mesocolon28 (65)128 (79)0.561 (0.299--1.050)0.0750.427 (0.215--0.848)0.015SOFA score10 (7--11)7 (4--9)1.261 (1.153--1.380)\<0.00011.291 (1.168--1.427)\<0.0001SAPS II score52 (45--61)44 (32--53)1.039 (1.019--1.060)\<0.0001----Initial use of piperacillin-tazobactam22 (51)105 (64)0.636 (0.350--1.157)0.117----Empiric antifungal therapy21 (49)49 (30)1.980 (1.089--3.601)0.029----Other *Enterobacteriaceae* ^b^5 (12)34 (21)0.538 (0.212--1.366)0.1950.342 (0.1219--0.961)0.0419Presence of *Candida* spp.19 (44)52 (32)1.569 (0.859--2.865)0.1502.641 (1.3471--5.179)0.0047Decreased SOFA score at day 317 (40)109 (67)0.372 (0.202--0.686)0.00150.311 (0.1632--0.593)0.0004Antibiotic strategy0.189 De-escalation19 (44)91 (56)0.488 (0.227--1.051)0.566 (0.2503--1.278)0.171 No change10 (23)21 (13)ReferenceReferenceReference Escalation14 (33)51 (31)0.627 (0.278--1.411)0.508 (0.2154--1.198)0.122*SAPS II* Simplified Acute Physiology Score II, *SOFA* Sequential Organ Failure Assessment^a^ *p* values are from Fisher exact tests or Wilcoxon tests^b^Other Enterobacteriaceae: analysis of all *Enterobacteriaceae* except *Escherichia coli*, *Klebsiella* spp., and *Enterobacter* spp.Fig. 2Kaplan-Meier survival curves of patients with de-escalation, without any change, and with escalation

The risk factors of in-hospital mortality on multivariate analysis were the emergency initial surgery (OR 2.81, 95 % CI 1.30--6.05, *p* = 0.008) and SOFA score on admission (OR 1.42, 95 % CI 1.24--1.62, *p* \< 0.001), while a decreased SOFA score at day 3 had a protective value (OR 0.14, 95 % CI 0.06--0.31, *p* \< 0.001) (c-index 0.852, 95 % CI 0.794--0.910, Hosmer-Lemeshow test *p* = 0.28).

Discussion {#Sec14}
==========

In this single-center observational study, de-escalation was performed in 53 % of patients treated for HCIAI. De-escalation concerned both antibacterial and antifungal therapies. The de-escalation procedure did not modify outcome. No initial clinical characteristic allowed identification of patients who were subsequently de-escalated. The presence of MDR bacteria and NFGNB as well as initial monotherapy were the most relevant factors limiting de-escalation. No emergence of resistant organisms was observed following de-escalation in the patients who underwent subsequent reoperation.

In the absence of data in the literature, we consider that our results provide an encouraging perspective for antibiotic de-escalation in ICU patients with abdominal sepsis. However, some limitations should be considered. Only 110 (35 %) of 311 patients treated for HCIAI were de-escalated. This highly selected population and the inclusion and exclusion criteria could be considered to constitute a weakness, but they allow selection of cases in which de-escalation is possible. Our local policy for empiric and definitive antibiotic use and the local characteristics of microbial flora must be considered cautiously and cannot be generalized. The long study duration may also have led to changes in the case mix or in antibiotic susceptibility patterns over time, although our analysis did not confirm this hypothesis. Another major limitation in the interpretation of our results is the lack of assessment of the quality of source control. The exclusion of patients undergoing early reoperation probably limited the importance of this issue. The absence of consensual definitions for de-escalation is another issue to be considered. The quality of de-escalation could be considered incomplete in many patients in whom there is room for improvement, and further reduction of antibiotic use or the use of narrow-spectrum empiric therapy should be considered.

Observational and retrospective studies have suggested that the de-escalation strategy is a safe approach in patients with severe sepsis or septic shock \[[@CR10]--[@CR12], [@CR15], [@CR18], [@CR19], [@CR22], [@CR35]\]. In recent European observational trials, the de-escalation rate ranged between 12.8 % of cases in a multicenter study in 41 French ICUs \[[@CR35]\] and 64 % in a single-center analysis focused on patients with severe sepsis and septic shock \[[@CR15]\]. Some prospective observational studies have suggested that mortality rates were at least not worse than those observed in patients not de-escalated \[[@CR16], [@CR36]--[@CR38]\]. In these reports, the lengths of ICU and hospital stay were not significantly different \[[@CR36], [@CR37]\]. Other authors have reported that de-escalation therapy could even significantly improve the prognosis \[[@CR4], [@CR13], [@CR39]\].

Prospective randomized trials addressing the issue of de-escalation are extremely rare. In a cohort of 290 patients treated for VAP, Micek et al. reported a decreased duration of antibiotic therapy and no significant differences in terms of secondary episodes of VAP and hospital mortality \[[@CR37]\]. In a group of 116 patients with severe sepsis either assigned or not to de-escalation, Leone et al. demonstrated that de-escalation was inferior to continuation of the initial antibiotic therapy with length of stay as the primary outcome parameter \[[@CR40]\]. Furthermore, antibiotic use was higher in the de-escalation group with a higher number of superinfections in the de-escalation group, but mortality was similar in the two groups \[[@CR40]\].

Only four retrospective, single-center, observational studies have described de-escalation practices for patients with peritonitis \[[@CR14], [@CR18], [@CR21], [@CR22]\], including between 113 and 229 patients, 10--38 % of whom presented with peritonitis. Although the observed de-escalation rate was 23--58 % in this population, none of these studies provided any information on the outcome of de-escalated patients. Our analysis is the first to focus on this surgical population, and our results suggest that de-escalation is safe and does not change the clinical outcome. On the basis of our results, a prospective multicenter study would appear to be feasible.

Obstacles to de-escalation have been clearly identified in the literature \[[@CR20]\]. The lack of appropriate empiric therapy is the first point to be considered \[[@CR13], [@CR22]\]. A high rate of MDR bacteria is an obvious reason for inadequate empiric therapy and consequently a recognized factor for limited de-escalation \[[@CR20]\]. However, although a recent analysis suggested that polymicrobial infection was a negative factor for de-escalation \[[@CR20]\], we did not observe this trend in the patients in our present study. Narrow-spectrum empiric therapy is obviously another important determinant limiting the frequency of de-escalation \[[@CR22]\]. However, narrow-spectrum empiric therapy is not an issue in intra-abdominal infections in which treatment should at least target anaerobes and Enterobacteriaceae \[[@CR41]\]. On the contrary, monotherapy has been proposed for the treatment of peritonitis \[[@CR41]\], and this policy could be a limitation on de-escalation \[[@CR18]\].

Poor or absent clinical improvement is another factor limiting de-escalation. In the present study, clinical and laboratory parameters of day 3 were unable to differentiate patients in whom de-escalation would be feasible and those in whom de-escalation could not be performed. Interestingly, Garnacho-Montero et al. reported lower SOFA scores at the time of de-escalation \[[@CR4]\], suggesting that the criteria for de-escalation may change from one population to another. This also means that prescribers should rely on microbiologic samples and the laboratory results more than any other criteria. The confidence of prescribers in their initial therapy is also based on two parameters that have been only minimally assessed in the literature: adequacy of source control and pharmacokinetics of anti-infective agents.

Several reports have indicated early improvement in patients who underwent de-escalation. Paskovaty et al., in a cohort of adult patients with cancer admitted to the ICU for severe sepsis, reported a significantly decreased SOFA score on day 5 \[[@CR42]\]. Two studies of patients with nosocomial pneumonia and ICU-acquired pneumonia reported early decreased SOFA and Acute Physiology and Chronic Health Evaluation II scores in the de-escalation groups \[[@CR43], [@CR44]\]. On the contrary, the incidence of organ failure at day 7 was similar in our patients with or without de-escalation. There is no obvious explanation for this discrepancy, but medical and surgical patients with sepsis may respond in different ways.

The rate of antibiotic escalation, although regularly discussed, is rarely assessed in the literature. In recent papers, this rate has ranged between 6.6 % and 7.9 % \[[@CR18], [@CR22]\]. However, Garnacho et al. reported escalation in 19 % of patients despite adequate empiric therapy \[[@CR4]\]. The mortality rate in this cohort was significantly increased compared with de-escalation or unchanged therapy (42.9 % versus 27.4 % and 32.6 %, respectively; *p* = 0.006) \[[@CR4]\], while Gonzales et al. reported that escalation did not induce any significant change in prognosis \[[@CR22]\]. In these two studies, the heterogeneous case mix resulted in complex analysis of these data. Few studies have reported the frequency and prognosis of escalation in peritonitis, but the effect of escalation appears to be less obvious in the present cohort.

Several beneficial effects of de-escalation have been hypothesized, including preservation of the patient's ecology and decreased emergence of MDR pathogens \[[@CR3], [@CR45]\]. However, these assumptions have never been clearly demonstrated. In the present study, we did not observe any significant change in the emergence of resistant pathogens in either the intra-abdominal site or extra-abdominal sites following de-escalation. This is not surprising, as the detection of emerging MDR organisms was not a specific goal of this study and changes of gut microbiota of our patients were not targeted. Similarly, de-escalation does not change the overall duration of therapy. This point, already mentioned in other studies \[[@CR22]\], was also observed in our present study.

An abundant literature exists regarding assessment of antibiotic de-escalation, but few data are available for antifungal agents. Several reports in candidemia or invasive candidiasis suggest that antifungal de-escalation is feasible \[[@CR46]--[@CR48]\], but no study has specifically addressed the issue of intra-abdominal infections. Unwarranted antifungal prescription is frequently reported in ICU patients, which raises both ecological and financial concerns \[[@CR49]\]. De-escalation and/or discontinuation of antifungal treatments could be proposed more frequently. Our data suggest that antifungal de-escalation could be feasible with no specific complications.

Conclusions {#Sec15}
===========

De-escalation is a reasonable option, even in patients with polymicrobial infections such as HCIAI. However, MDR bacteria and NFGNB remain major obstacles to implementation of de-escalation. The prescriber must consider whether the determinants of success have been met, especially an adequate empiric therapy. Although our results are reassuring, this strategy needs to be confirmed in a multicenter, randomized, prospective trial.

Key messages {#Sec16}
============

De-escalation is a reasonable option, even in polymicrobial infections such as health care-associated intra-abdominal infections.Multidrug-resistant bacteria and nonfermenting Gram-negative bacilli remain a major obstacle in de-escalation.The key determinants for de-escalation are susceptible microorganisms and adequate empiric therapy.

ESBL

:   extended-spectrum β-lactamase

HCIAI

:   health care--associated intra-abdominal infection

ICU

:   intensive care unit

IQR

:   interquartile range

MDR

:   multidrug-resistant

MRSA

:   methicillin-resistant *Staphylococcus aureus*

NFGNB

:   nonfermenting Gram-negative bacilli

SAPS II

:   Simplified Acute Physiology Score II

SOFA

:   Sequential Organ Failure Assessment

VAP

:   ventilator-associated pneumonia

WBC

:   white blood cell count
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